MarketBeat
15 Sept 2026, 08:03 UTC · 2h ago
Verdict
Headline leans bearish. We score CRBP +0.80 across four claims.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
CRB-913 achieved an average 5% placebo-adjusted weight loss at 12 weeks at the 60mg dose.
Newreported top-line results in article published 2026-09-15
So whatMatching the early profile of oral GLP-1s positions CRBP as a viable alternative or additive therapy by 2027.
More positive than 91% of claims this week
The Phase 1b study recorded no suicidality and no serious treatment-related adverse events across dose cohorts.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Newreported top-line results in article published 2026-09-15
More positive than 85% of claims this week
Corbus intends to begin a Phase 2 monotherapy trial, CANYON-2, as quickly as possible next year.
Newcompany plans reported in article dated 2026-09-15
So whatThe transition to Phase 2 in 2027 will likely trigger a need for new financing or a strategic partnership.
More positive than 66% of claims this week
CRB-913 showed lower nausea, vomiting, and constipation rates than published studies of oral semaglutide and orforglipron.
Newreported top-line results in article published 2026-09-15
So whatSuperior GI tolerability could expand the addressable patient market to those who discontinue GLP-1s due to side effects.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported positive Phase 1b trial results for its obesity drug CRB-913, demonstrating weight loss and a favorable safety profile.
More negative than 65% of ticker scores this week
The article mentions a discontinued drug from Novo Nordisk as a point of comparison for Corbus's superior brain penetration profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1d ago
—
CRBP hasn't traded since this ran. Last close $8.08 (Sep 14); the reaction starts at the next open.
CRBP chart →
